1. Knight, M, Bunch, K, Tuffnell, D. et al. (Eds.) On behalf of MBRRACE-UK. Saving Lives, Improving Mothers' Care - Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2016–18. Oxford: National Perinatal Epidemiology Unit, University of Oxford 2020.
Google Scholar2. Laster, M, Shen, JI, Norris, KC. Kidney disease among African Americans: a population perspective. Am J Kidney Dis 2018; 72: S3–S7.
Google Scholar | Crossref | Medline3. Mays, VM, Cochran, SD, Barnes, NW. Race, race-based discrimination, and health outcomes among African Americans. Annu Rev Psychol 2007; 58: 201–225.
Google Scholar | Crossref | Medline | ISI4. Public Health Outcomes Framework: Health Equity Report Focus on ethnicity Public Health Outcomes Framework: Health Equity Report-Focus on ethnicity, www.facebook.com/PublicHealthEngland (2017, accessed March 30, 2021).
Google Scholar5. Buchanan, L, Bui, Q, Patel, J. Black Lives Matter May Be the Largest Movement in U.S. History. The New York Times, July 3, 2020.
Google Scholar6. Freedman, BI, Limou, S, Ma, L, et al. APOL1-associated nephropathy: a key contributor to racial disparities in CKD. Am J Kidney Dis 2018; 72: S8–S16.
Google Scholar | Crossref | Medline7. Genovese, G, Friedman, DJ, Ross, MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841–845.
Google Scholar | Crossref | Medline | ISI8. Tzur, S, Rosset, S, Shemer, R, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010; 128: 345–350.
Google Scholar | Crossref | Medline9. Page, NM, Butlin, DJ, Lomthaisong, K, et al. The human apolipoprotein L gene cluster: identification, classification, and sites of distribution. Genomics 2001; 74: 71–78.
Google Scholar | Crossref | Medline10. Dummer, PD, Limou, S, Rosenberg, AZ, et al. APOL1 kidney disease risk variants-an evolving landscape. Doi: 10.1016/j.semnephrol.2015.04.008.
Google Scholar | Crossref11. Madhavan, SM, O’Toole, JF, Konieczkowski, M, et al. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 2011; 22: 2119–2128.
Google Scholar | Crossref | Medline12. Johnstone, DB, Shegokar, V, Nihalani, D, et al. APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis. PLoS ONE 2012; 7: e51546.
Google Scholar | Crossref | Medline13. Nally, JV . Chronic kidney disease in African Americans: puzzle pieces are falling into place. Clevel Clin J Med 2017; 84: 855–862.
Google Scholar | Crossref | Medline14. Bruggeman, LA, O’Toole, JF, Ross, MD, et al. Plasma apolipoprotein L1 levels do not correlate with CKD. J Am Soc Nephrol 2014; 25: 634–644.
Google Scholar | Crossref | Medline15. Lee, BT, Kumar, V, Williams, TA, et al. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant 2012; 12: 1924–1928.
Google Scholar | Crossref | Medline | ISI16. Freedman, BI, Julian, BA, Pastan, SO, et al. Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure. Am J Transplant 2015; 15: 1615–1622.
Google Scholar | Crossref | Medline | ISI17. Santoriello, D, Husain, SA, de Serres, SA, et al. Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts. Kidney Int 2018; 94: 1189–1198.
Google Scholar | Crossref | Medline18. Shah, PB, Cooper, JE, Lucia, MS, et al. APOL1 Polymorphisms in a deceased donor and early presentation of collapsing glomerulopathy and focal segmental glomerulosclerosis in two recipients. Am J Transplant 2016; 16: 1923–1927.
Google Scholar | Crossref | Medline19. Beckerman, P, Bi-Karchin, J, Park, ASD, et al. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nat Med 2017; 23: 429–438.
Google Scholar | Crossref | Medline20. Kopp, JB, Anders, HJ, Susztak, K, et al. Podocytopathies. Nat Rev Dis Primers 2020; 6: 1–24.
Google Scholar | Crossref | Medline21. Kopp, JB, Nelson, GW, Sampath, K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22: 2129–2137.
Google Scholar | Crossref | Medline22. SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103–2116.
Google Scholar | Crossref | Medline | ISI23. Appel, LJ, Wright, JT, Greene, T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363: 918–929.
Google Scholar | Crossref | Medline | ISI24. Wright, JT, Bakris, G, Greene, T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. J Am Med Assoc 2002; 288: 2421–2431.
Google Scholar | Crossref | Medline | ISI25. Peralta, CA, Bibbins-Domingo, K, Vittinghoff, E, et al. APOL1 genotype and race differences in incident albuminuria and renal function decline. J Am Soc Nephrol 2016; 27: 887–893.
Google Scholar | Crossref | Medline26. Parsa, A, Kao, WHL, Xie, D, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013; 369: 2183–2196.
Google Scholar | Crossref | Medline | ISI27. Annual Data Report | USRDS, https://www.usrds.org/annual-data-report/ (accessed March 30, 2021).
Google Scholar28. Lertdumrongluk, P, Streja, E, Rhee, CM, et al. Survival advantage of African American dialysis patients with End-stage renal disease causes related to APOL1. Cardiorenal Med 2019; 9: 212–221.
Google Scholar | Crossref | Medline29. Ito, K, Bick, AG, Flannick, J, et al. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res 2014; 114: 845–850.
Google Scholar | Crossref | Medline | ISI30. Bick, AG, Akwo, E, Robinson-Cohen, C, et al. Association of APOL1 risk alleles with cardiovascular disease in blacks in the million veteran program. Circulation 2019; 140: 1031–1040.
Google Scholar | Crossref | Medline31. Nakimuli, A, Chazara, O, Byamugisha, J, et al. Pregnancy, parturition and preeclampsia in women of African ancestry. Am J Obstet Gynecol 2014; 210: 510–520.e1.
Google Scholar | Crossref | Medline32. Miller, AK, Azhibekov, T, O’Toole, JF, et al. Association of preeclampsia with infant APOL1 genotype in African Americans. BMC Med Genet 2020; 21(1): 110. DOI: 10.1186/s12881-020-01048-4.
Google Scholar | Crossref | Medline33. Bruggeman, LA, Wu, Z, Luo, L, et al. APOL1-G0 or APOL1-G2 transgenic models develop preeclampsia but not kidney disease. J Am Soc Nephrol 2016; 27: 3600–3610.
Google Scholar | Crossref | Medline34. Uhlén, M, Fagerberg, L, Hallström, BM, et al. Proteomics. Tissue-based map of the human proteome. Science 2015; 347(6220): 1260419. DOI: 10.1126/science.1260419.
Google Scholar | Crossref | Medline35. Tubbergen, P, Lachmeijer, AMA, Althuisius, SM, et al. Change in paternity: a risk factor for preeclampsia in multiparous women? J Reprod Immunol 1999; 45: 81–88.
Google Scholar | Crossref | Medline36. Galaviz-Hernandez, C, Sosa-Macias, M, Teran, E, et al. Paternal determinants in preeclampsia. Front Physiol 2019; 10: 1870.
Google Scholar | Crossref37. Thakoordeen-Reddy, S, Winkler, C, Moodley, J, et al. Maternal variants within the apolipoprotein L1 gene are associated with preeclampsia in a South African cohort of African ancestry. Eur J Obs Gynecol Reprod Biol 2020; 246: 129–133.
Google Scholar | Crossref | Medline38. Reidy, KJ, Hjorten, RC, Simpson, CL, et al. Fetal—not maternal—APOL1 genotype associated with risk for preeclampsia in those with African ancestry. Am J Hum Genet 2018; 103: 367–376.
Google Scholar | Crossref | Medline39. Sampson, MG, Robertson, CC, Martini, S, et al. Integrative genomics identifies novel associations with APOL1 risk genotypes in black Neptune subjects. J Am Soc Nephrol 2016; 27: 814–823.
Google Scholar | Crossref | Medline40. Moxey-Mims, M . Kidney disease in African American children: biological and nonbiological disparities. Am J Kidney Dis 2018; 72: S17–S21.
Google Scholar | Crossref | Medline41. Mills, KT, Xu, Y, Zhang, W, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int 2015; 88: 950–957.
Google Scholar | Crossref | Medline | ISI42. Piccoli, GB, Cabiddu, G, Attini, R, et al. Risk of adverse pregnancy outcomes in women with CKD. J Am Soc Nephrol 2015; 26: 2011–2022.
Google Scholar | Crossref | Medline | ISI43. Bramham, K, Briley, AL, Seed, PT, et al. Pregnancy outcome in women with chronic kidney disease: a prospective cohort study. Reprod Sci 2011; 18: 623–630.
Google Scholar | SAGE Journals | ISI44. Magee, LA, Abalos, E, von Dadelszen, P, et al. Control of hypertension in pregnancy. Curr Hypertens Rep 2009; 11: 429–436.
Google Scholar | Crossref | Medline | ISI45. Heymann, J, Winkler, CA, Hoek, M, et al. Therapeutics for APOL1 nephropathies: putting out the fire in the podocyte. Nephrol Dial Transplant 2017; 32: i65–i70.
Google Scholar | Crossref | Medline46. Umeukeje, EM, Young, BA, Fullerton, SM, et al. You are just now telling us about this? African American perspectives of testing for genetic susceptibility to kidney disease. J Am Soc Nephrol 2019; 30: 526–530.
Google Scholar | Crossref | Medline47. Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis - Full Text View - ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT04340362 (accessed March 30, 2021).
Google Scholar